(Q33416734)

English

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

Mohammed Milhem

object named as

Mohammed Milhem

7

0 references

author name string

Chang Xia

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Roberto Leon-Ferre

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Douglas Laux

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jeremy Deutsch

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Brian J Smith

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Melanie Frees

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

26 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

74

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

691-697

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

copyright license

Creative Commons Attribution 4.0 International

26 July 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Insulin and insulin-like growth factor signalling in neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Epigenetics as a mechanism driving polygenic clinical drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Decitabine: a historical review of the development of an epigenetic drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Histone-deacetylase inhibitors for the treatment of cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Drug resistance in human melanoma: mechanisms and therapeutic opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

DNA hypermethylation in tumorigenesis: epigenetics joins genetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

21 June 2018

Combining epigenetic and cytotoxic therapy in the treatment of solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2501-1

21 January 2018

Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2501-1

21 January 2018

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2501-1

21 January 2018

Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2501-1

21 January 2018

Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2501-1

21 January 2018

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2501-1

21 January 2018

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2501-1

21 January 2018

Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2501-1

21 January 2018

5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4175037

31 October 2018

5-AZA-2'-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2501-1

21 January 2018

Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR)

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2501-1

21 January 2018

The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/25062770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25062770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/25062770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-014-2501-1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33416734&oldid=2195340909"